a GSK , Wavre , Belgium.
b GSK , Singapore.
Hum Vaccin Immunother. 2017 Oct 3;13(10):2213-2221. doi: 10.1080/21645515.2017.1345399. Epub 2017 Jul 14.
The aim of this study was to compare the public health impact of introducing 2 Herpes Zoster (HZ) vaccines, Zoster Vaccine Live (ZVL) versus a non-live adjuvanted subunit candidate vaccine (HZ/su), in the German population aged 50+ years split into 3 age cohorts, i.e. 50-59, 60-69 and 70+ years, respectively. A multi-cohort static Markov model was developed following age cohorts over their lifetime. Demographic data were obtained from the German federal statistical office. HZ incidence and the proportion of HZ individuals developing post-herpetic neuralgia (PHN) were derived from German specific sources. Age-specific vaccine efficacy and waning rates were based on published clinical trial data. Vaccine coverage for both vaccines was assumed to be 40%, with compliance of the second dose of the HZ/su vaccine of 70%. Sensitivity analyses were performed to assess the robustness of the results. It was estimated that, over the remaining lifetime since vaccination, the HZ/su vaccine would reduce the number of HZ cases by 725,233, 533,162 and 486,794 in the 3 age cohorts, respectively, compared with 198,477, 196,000 and 104,640, using ZVL. The number needed to vaccinate (NNV) to prevent one HZ case ranged from 8 to 11 using the HZ/su vaccine compared with 20 to 50 using ZVL. Corresponding NNV to prevent one PHN case ranged from 39 to 53 using the HZ/su vaccine compared with 94 to 198 using ZVL. Due to the higher, sustained vaccine efficacy, the candidate HZ/su vaccine demonstrated superior public health impact compared with ZVL.
本研究旨在比较两种带状疱疹（HZ）疫苗，即带状疱疹减毒活疫苗（ZVL）和非活佐剂亚单位候选疫苗（HZ/su）在德国 50 岁以上人群中的公共卫生影响，该人群分为 3 个年龄组，即 50-59 岁、60-69 岁和 70 岁以上。根据年龄组，采用多队列静态马尔可夫模型对队列进行终生随访。人口统计数据来自德国联邦统计局。HZ 发病率和发生带状疱疹后神经痛（PHN）的 HZ 个体比例来自德国特定来源。年龄特异性疫苗效力和衰减率基于已发表的临床试验数据。两种疫苗的疫苗覆盖率均假设为 40%，HZ/su 疫苗的第二剂接种率为 70%。进行了敏感性分析以评估结果的稳健性。估计在接种后的剩余寿命内，与 ZVL 相比，HZ/su 疫苗将分别减少 3 个年龄组中的 HZ 病例数 725,233、533,162 和 486,794；在 3 个年龄组中，使用 ZVL 将分别减少 198,477、196,000 和 104,640。使用 HZ/su 疫苗预防 1 例 HZ 病例的接种人数（NNV）为 8-11，而使用 ZVL 疫苗则为 20-50。使用 HZ/su 疫苗预防 1 例 PHN 病例的 NNV 为 39-53，而使用 ZVL 疫苗则为 94-198。由于更高和持续的疫苗效力，候选 HZ/su 疫苗与 ZVL 相比具有更好的公共卫生影响。
